2024 Revenues ($USD) : $3.68B
Ipsen delivered solid financial results in 2024, with total sales growth of 9.9% at constant exchange rates to €3.4B. Growth was driven by strong performance across all therapeutic areas, with a notable 67.4% increase in the Rare Diseases portfolio. Core operating income grew by 10.8% to €1.11B, with an improved margin of 32.6%. For 2025, Ipsen projects total sales growth greater than 5.0% and continues to expand its pipeline through strategic partnerships.